Vesalius Biocapital offers venture capital
to young European innovative life science companies

logo
Wednesday, June 21, 2017 News

Pluriomics’ Pluricyte® Cardiomyocytes selected by Wageningen University as model system to elucidate poorly understood methadone toxicity mechanisms

Pluriomics, an emerging Belgian/Dutch biotechnology company whose mission is to deliver cardiac drug discovery and safety solutions based on its best-in-class human iPSC-derived cardiomyocyte technology, today announced its Pluricyte® Cardiomyocytes were selected by the laboratory of Dr. Jochem Louisse from Wageningen University to evaluate in vitro cardiotoxic effect of methadone and combination effects with other compounds.

Pluriomics is a leading expert in human cardiovascular stem cell technology, disease modeling and cell-based assays development for cardiovascular drug discovery. Pluriomics’ proprietary Pluricyte® Cardiomyocytes are fully functional human iPSC-derived cardiomyocytes exhibiting unique electrophysiological characteristics that make them exceptionally well-suited for implementation in contractility-, biochemistry- and electrophysiology-based assays to improve drug safety and efficacy screenings. Due to their unique characteristics and to their relatively high level of maturity, when compared to other human stem cell-derived cardiomyocytes, Pluriomics’ Pluricyte® Cardiomyocytes were chosen by Dr. Jochem Louisse, from the Division of Toxicology of Wageningen University for his Research Project that assesses the in vitro cardiotoxic effect of methadone and the combination effects with other compounds. The goal of Dr. Louisse’s project is to use the in vitro toxicity data obtained in human models to predict human dose-dependent toxicity by translating in vitro data to the in vivo situation using human physiologically based kinetic (PBK) models, with the aim of showing that human toxicity can be predicted without in vivo testing. In a next step, the approach will be extended by including the effect of co-exposure to diazepam in the approach, which is a drug that is regularly taken by methadone users and which has been reported to increase the risks of methadone-induced cardiotoxicity.

Jochem Louisse, Scientist at Wageningen University commented: “The aim of this project is to provide a proof-of-principle that human toxicity can be predicted using physiologically based kinetic (PBK) modeling-based reverse dosimetry, using methadone as a model compound and cardiotoxicity as the toxicity endpoint. We are delighted to use Pluriomics’ Pluricyte® Cardiomyocytes to assess the concentration-dependent in vitro cardiotoxicity of methadone and its metabolites, as well as combination effects at the toxicodynamic level with other compounds.”

Celine Hechard, VP Business Development & Marketing at Pluriomics BV, commented: “We are pleased Dr. Jochem Louisse selected our Pluricyte® Cardiomyocytes to evaluate cardiotox effect of methadone and other compounds. As a cardiovascular expert in in vitro drug discovery, Pluriomics aims to support this kind of approaches which validate in vitro assay predictivity”.
 
For more information please contact:
Pluriomics
celine.hechard(at)pluriomics.com
+31 (0)71 332 2230
 
About Pluriomics
Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human induced pluripotent stem cell derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics’ Pluricyte® Cardiomyocytes and innovative technologies are exceptionally well suited for implementation in various stages of drug discovery to improve decision-making, reduce attrition rates and provide an alternative for animal testing.
Pluriomics offers unique cardiac drug discovery and safety assessment solutions based on its best-in-class human iPSC-derived cardiomyocyte cellular assays. The company aims to contribute to the efficiency of the drug discovery and development process by delivering products and services for early discovery and safety assessment.

The company is backed by private investors, Venture Funds and strategic investment from regional investment funds (Vesalius Biocapital, InnovationQuarter, S.R.I.W, SambrInvest, SFPI-FPIM). 
Pluriomics is based in Leiden, The Netherlands and in Gosselies, Belgium.
For more information please visit www.pluriomics.com
 To view this press release as a PDF file, click here